cobimetinib + venetoclax + atezolizumab

This is an investigational combination therapy consisting of **cobimetinib** (an orally available selective inhibitor of MEK1/2 in the MAPK pathway), **venetoclax** (a small molecule inhibitor of the anti-apoptotic protein B-cell lymphoma 2), and **atezolizumab** (a monoclonal antibody targeting programmed death-ligand 1, a checkpoint inhibitor). The regimen is being studied primarily for relapsed/refractory multiple myeloma, with the mechanistic rationale that combining MEK inhibition, BCL-2 inhibition, and immune checkpoint blockade may enhance tumor cell death and antitumor immune responses, especially in patients with specific molecular signatures such as t(11;14) or MAPK pathway mutations[1][3][5][6]. All three agents are already approved for other indications individually, but this triple combination is under evaluation in early-phase clinical trials for multiple myeloma.